5-羟基-8-(4-羟基-7-甲基-5,8-二氧代萘-1-基)-2-甲基萘-1,4-二酮 | 33927-59-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 5-羟基-8-(4-羟基-7-甲基-5,8-二氧代萘-1-基)-2-甲基萘-1,4-二酮
• 英文名称: 8,8'-biplumbagin
• 英文别名: maritinone；Maritinon；5-hydroxy-8-(4-hydroxy-7-methyl-5,8-dioxonaphthalen-1-yl)-2-methylnaphthalene-1,4-dione
• CAS: 33927-59-2
• 化学式: C₂₂H₁₄O₆
• 分子量: 374.35
• InChiKey: XCRMWTKECYDCOD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  28
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  109
• 氢给体数：
  2
• 氢受体数：
  6

安全信息

• 海关编码：
  2914400090

反应信息

• 作为反应物：
  描述：

  5-羟基-8-(4-羟基-7-甲基-5,8-二氧代萘-1-基)-2-甲基萘-1,4-二酮 、 碘甲烷 在 silver(l) oxide 作用下， 以 氯仿 为溶剂， 生成 Maritinon dimethylaether
  参考文献：
  名称：

  Higa, Matsutake, Chemical and pharmaceutical bulletin, 1988, vol. 36, # 8, p. 3234 - 3236

  摘要：

  DOI：
• 作为产物：
  描述：

  Maritinon-diacetat 在 硫酸 作用下， 以92%的产率得到5-羟基-8-(4-羟基-7-甲基-5,8-二氧代萘-1-基)-2-甲基萘-1,4-二酮
  参考文献：
  名称：

  Laatsch, Hartmut, Liebigs Annalen der Chemie, 1985, # 12, p. 2420 - 2442

  摘要：

  DOI：

文献信息

• HIGA, MATSUTAKE, CHEM. AND PHARM. BULL., 36,(1988) N 8, C. 3234-3236
  作者：HIGA, MATSUTAKE

  DOI：——

  日期：——
• Treatment of Tumors with Activated Mesenchymal Stem Cells
  申请人：THE TEXAS A&M UNIVERSITY SYSTEM

  公开号：US20150272992A1

  公开（公告）日：2015-10-01

  A method of treating a tumor in an animal by administering to the animal mesenchymal stem cells that have been contacted with a stimulating, or activating agent, such as TNF-a, that stimulates the mesenchymal stem cells to express increased amounts of at least one agent, such as TRAIL and/or DKK-3, that inhibits, prevents, or destroys the growth of tumors. The stimulated, or activated mesenchymal stem cells may be administered in combination with at least one chemotherapeutic agent, such as doxorubicin.
• [EN] TREATMENT OF TUMORS WITH ACTIVATED MESENCHYMAL STEM CELLS<br/>[FR] TRAITEMENT DE TUMEURS À L'AIDE DE CELLULES SOUCHES MÉSENCHYMATEUSES ACTIVÉES
  申请人：TEXAS A & M UNIV SYS

  公开号：WO2014066122A1

  公开（公告）日：2014-05-01

  A method of treating a tumor in an animal by administering to the animal mesenchymal stem cells that have been contacted with a stimulating, or activating agent, such as TNF-a, that stimulates the mesenchymal stem cells to express increased amounts of at least one agent, such as TRAIL and/or DKK-3, that inhibits, prevents, or destroys the growth of tumors. The stimulated, or activated mesenchymal stem cells may be administered in combination with at least one chemotherapeutic agent, such as doxorubicin.

表征谱图